Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis

Zhan Li; Songcheng Yin; Lei Zhang; Weiguang Liu; Bo Chen

doi:10.18632/oncotarget.14860

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis

Zhan Li, Songcheng Yin, Lei Zhang, Weiguang Liu and Bo Chen _

PDF | HTML | How to cite

Oncotarget. 2017; 8:16445-16455. https://doi.org/10.18632/oncotarget.14860

Metrics: PDF 2764 views | HTML 3196 views | ?

Abstract

Zhan Li1,*, Songcheng Yin2,*, Lei Zhang1, Weiguang Liu1, Bo Chen1

1Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China

2Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China

*These authors contribute equally to this work

Correspondence to:

Bo Chen, email: [email protected]

Keywords: E-cadherin, breast cancer, prognosis, biomarker, meta-analysis

Received: July 15, 2016 Accepted: January 16, 2017 Published: January 27, 2017

ABSTRACT

The prognostic value of E-cadherin expression in patients with breast cancer has been studied for years, yet results remain controversial. We thus performed a comprehensive evaluation of the association between E-cadherin expression and prognosis through a meta-analysis. The databases PubMed, Embase and Cochrane Library were searched. A total of 7,353 patients from 33 studies were subject to final analysis. The results showed there was a significant association between reduced expression of E-cadherin and overall survival (OS) (HR 1.79, 95% CI 1.41–2.27) and disease-free survival (DFS) (HR 1.62, 95% CI 1.31–1.99) in breast cancer. Downregulated expression of E-cadherin significantly correlated with tumor histological grade (OR 1.44, 95% CI 1.06–1.96), TNM stage (OR 2.44, 95% CI 1.75–3.41), tumor size (OR 1.38, 95% CI 1.18–1.60), lymph node status (OR 1.55, 95% CI 1.15–2.10), and progesterone receptor status (OR 1.44, 95% CI 1.10–1.88).This meta-analysis suggested that reduced E-cadherin expression might be a predictor of a poorer prognosis and could be a potentially new gene therapy target for breast cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14860

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis

Abstract